The mechanism: Every June, the Federal Reserve runs the largest U.S. banks through a hypothetical recession and spits out a Stress Capital Buffer (SCB) — the extra capital cushion each bank must hold on top of minimums. That number has swung by a percentage point or more year to year based on modeling noise, not fundamentals, forcing banks to hold a buffer against the buffer before committing to buybacks. In April 2025 the Fed proposed averaging two consecutive years of stress test results to calculate the SCB, and it has since delayed implementing new capital requirements while it works through the rulemaking — explicitly to cut that volatility. Less volatility in the SCB doesn't change a bank's earnings power. It changes how much capital a bank's board is willing to authorize for repurchase right now, because the tail-risk of a sudden capital-requirement spike that would force clawing back a buyback program is smaller. That's a governance and capital-allocation catalyst, and it moves ahead of — not because of — any change in loan growth or net interest margin.
The Real Winner of Fed Stress Test Reform Isn't the Banks — It's Their Buyback Button
A Fed proposal to average stress capital buffer results over two years won't make banks more profitable, but it will make their capital-return math predictable enough to unlock steadier, larger buybacks and dividends at JPMorgan and Bank of America.
| Ticker | Company | 1-year change |
|---|---|---|
| JPM | JPMorgan Chase | +11.0% |
| BAC | Bank of America | +20.0% |
| GS | Goldman Sachs | +33.4% |
A smoother stress test doesn't make a bank more profitable — it makes its board more willing to press the buyback button.
Who cashes in:
- JPMorgan JPM — the largest and most stress-tested bank in the country, JPM already has the most excess capital of any G-SIB and the biggest single buyback authorization in U.S. banking. A steadier SCB removes the main constraint management has cited for not deploying that excess faster; expect authorization size and repurchase pace to become less lumpy quarter to quarter.
- Bank of America BAC — BAC has historically run tighter to its regulatory minimums than JPM, meaning SCB volatility hit its buyback flexibility harder in bad-scenario years. A smoothed, averaged buffer gives BAC's board more confidence to commit to a multi-quarter repurchase cadence instead of pausing when a single year's hypothetical scenario runs hot.
- Goldman Sachs GS and Morgan Stanley MS — both carry markets-heavy balance sheets that generate the most SCB volatility under the Fed's global market shock component. The averaging fix disproportionately dampens their swings, making both more reliable dividend-growers and buyback executors even though neither is a household retail name in this story.
Who is exposed: Citigroup C benefits least — its capital-return story is still constrained by its own multi-year consent-order remediation and transformation costs, not by SCB volatility, so a smoother stress test buffer doesn't unlock anything Citi wasn't already gating for internal reasons. Charles Schwab (SCHW) isn't a stress-test bank in the CCAR sense at all; it's a broker-dealer/bank hybrid that doesn't get this specific regulatory tailwind, so it's a relative laggard in any capital-return re-rating trade built on this theme.
The play: This is a capital-allocation catalyst, not an earnings catalyst — watch each bank's next capital plan disclosure and buyback authorization size, not next quarter's EPS, for confirmation. What to watch: the Fed's final rule on SCB averaging and any further delay notices at federalreserve.gov, plus each bank's post-stress-test capital action announcement in late June/July.
Source: original report ↗
Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $40/moJoin the owners who run ahead of the industry. Cancel anytime, one click.